Amicus Therapeutics, Inc. Stock London S.E.
Stocks
0HF9
US03152W1099
Biotechnology & Medical Research
| Market Cap | 4.55B 3.95B 3.67B 3.38B 6.38B 434B 6.49B 43.45B 17.01B 216B 17.09B 16.71B 725B | P/E 2024 |
-51.1x | P/E 2025 | -162x |
|---|---|---|---|---|---|
| Enterprise Value | 4.7B 4.08B 3.79B 3.5B 6.58B 449B 6.7B 44.87B 17.57B 223B 17.65B 17.26B 749B | EV / Sales 2024 |
5.69x | EV / Sales 2025 | 7.18x |
| Free-Float |
99.31% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Amicus Therapeutics, Inc.
| 1 day | +17.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
George Davis
PSD | President | 55 | 27/04/2026 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +17.93% | +18.15% | - | - | 4.55B | |
| -0.80% | +6.30% | -1.72% | +13.00% | 48.95B | |
| -3.95% | +14.70% | +24.15% | +6.27% | 40.75B | |
| +6.22% | +1.81% | +419.17% | +632.08% | 38.46B | |
| -1.57% | -1.44% | +7.38% | +50.35% | 36.38B | |
| +5.56% | +11.70% | +11.64% | +51.50% | 28.45B | |
| -0.39% | -0.63% | - | - | 16.62B | |
| -1.13% | -4.54% | +32.10% | +128.42% | 16.33B | |
| -7.10% | -2.81% | -8.80% | -34.16% | 13.65B | |
| -0.06% | -2.81% | +3.16% | +10.08% | 13.56B | |
| Average | +1.56% | +6.06% | +60.88% | +107.19% | 28.13B | |
| Weighted average by Cap. | +0.55% | +7.20% | +76.39% | +127.97% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 528M 459M 426M 393M 740M 50.44B 754M 5.04B 1.98B 25.05B 1.98B 1.94B 84.24B | 634M 551M 512M 472M 889M 60.55B 905M 6.06B 2.37B 30.07B 2.38B 2.33B 101B |
| Net income | -56.11M -48.73M -45.26M -41.74M -78.62M -5.36B -80.04M -536M -210M -2.66B -211M -206M -8.95B | -27.11M -23.55M -21.87M -20.17M -37.99M -2.59B -38.68M -259M -101M -1.29B -102M -99.58M -4.32B |
| Net Debt | 194M 168M 156M 144M 271M 18.49B 276M 1.85B 724M 9.18B 727M 711M 30.89B | 149M 129M 120M 111M 209M 14.21B 212M 1.42B 556M 7.06B 559M 547M 23.73B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
